TME Pharma N.V. (EPA:ALTME)

TME Pharma Statistics

Total Valuation

TME Pharma has a market cap or net worth of EUR 6.77 million. The enterprise value is 6.43 million.

Market Cap	6.77M
Enterprise Value	6.43M

Important Dates

The next estimated earnings date is Thursday, April 23, 2026.

Earnings Date	Apr 23, 2026
Ex-Dividend Date	n/a

Share Statistics

TME Pharma has 94.09 million shares outstanding. The number of shares has increased by 307.74% in one year.

Current Share Class	94.09M
Shares Outstanding	94.09M
Shares Change (YoY)	+307.74%
Shares Change (QoQ)	+110.92%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	4.19%
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	250.91
PB Ratio	-11.89
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.41
EV / Sales	238.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.35

Financial Position

The company has a current ratio of 0.79

Current Ratio	0.79
Quick Ratio	0.73
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.36
Interest Coverage	-85.73

Financial Efficiency

Return on equity (ROE) is -917.95% and return on invested capital (ROIC) is -204.72%.

Return on Equity (ROE)	-917.95%
Return on Assets (ROA)	-106.45%
Return on Invested Capital (ROIC)	-204.72%
Return on Capital Employed (ROCE)	782.11%
Weighted Average Cost of Capital (WACC)	7.15%
Revenue Per Employee	2,250
Profits Per Employee	-381,333
Employee Count	12
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -0.55% in the last 52 weeks. The beta is 0.75, so TME Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	-0.55%
50-Day Moving Average	0.07
200-Day Moving Average	0.09
Relative Strength Index (RSI)	55.71
Average Volume (20 Days)	379,282

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TME Pharma had revenue of EUR 27,000 and -4.58 million in losses. Loss per share was -0.07.

Revenue	27,000
Gross Profit	27,000
Operating Income	-4.46M
Pretax Income	-4.58M
Net Income	-4.58M
EBITDA	-4.50M
EBIT	-4.46M
Loss Per Share	-0.07

Balance Sheet

The company has 2.06 million in cash and 1.72 million in debt, with a net cash position of 340,000 or 0.00 per share.

Cash & Cash Equivalents	2.06M
Total Debt	1.72M
Net Cash	340,000
Net Cash Per Share	0.00
Equity (Book Value)	-570,000
Book Value Per Share	-0.01
Working Capital	-588,000

Cash Flow

In the last 12 months, operating cash flow was -4.76 million and capital expenditures -12,000, giving a free cash flow of -4.77 million.

Operating Cash Flow	-4.76M
Capital Expenditures	-12,000
Free Cash Flow	-4.77M
FCF Per Share	-0.05

Margins

Gross Margin	100.00%
Operating Margin	-16,511.11%
Pretax Margin	-16,948.15%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TME Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-307.74%
Shareholder Yield	-307.74%
Earnings Yield	-67.55%
FCF Yield	-70.43%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 28, 2022. It was a reverse split with a ratio of 0.01.

Last Split Date	Jul 28, 2022
Split Type	Reverse
Split Ratio	0.01

Scores

TME Pharma has an Altman Z-Score of -128.82. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-128.82
Piotroski F-Score	n/a